Market Research Logo

Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019

Global Chronic Kidney Disease (CKD) Drugs Market 2015-2019

About According to WHO, CKD is not only common, treatable, and harmful but also a major contributing factor to the incidence and outcomes of at least three of the diseases that are targeted by WHO (hypertension, diabetes, and CVD). CKD is mainly defined as a reduced GFR, increased urinary albumin excretion, or both, and is growing public health issue. CKD is classified into five stages (stages 1-5) according to renal function and the level of urinary protein excretion as measured by eGFR which is derived from race, gender, age, and serum creatinine concentration.

TechNavio's analysts forecast the Global CKD Drugs market to grow at a CAGR of 1.21 percent over the period 2014-2019.

Covered in this Report

The Global CKD Drugs Market can be divided into two segments: Route of Administration which includes oral, SC, and IV and Mechanism of Action which includes ARBs, ACEIs, ESAs, PH Binders, and Vasodilators. This report covers the present scenario and the growth prospects of the Global CKD Drugs market for the period 2014–2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of CKD that are available in the market.

TechNavio's report, the Global CKD Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA and APAC regions; it also covers the Global CKD Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.Key Regions

  • Americas
  • EMEA
  • APAC
Key Vendors
  • Actavis PLC
  • Amgen Inc.
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd
  • Sanofi
Other Prominent Vendors
  • Abbott Laboratories
  • Akebia Therapeutics
  • AMAG Pharmaceuticals
  • Cara Therapeutics
  • FibroGen
  • Keryx Biopharmaceuticals
  • Reata Pharmaceuticals
  • OPKO Health
  • Pharmacosmos
  • Raptor Pharmaceuticals
  • Regulus Therapeutics
  • Rockwell Medical
  • Shield Therapeutics
  • Takeda Pharmaceuticals
  • Vifor Pharma Ltd
  • Xenetic Biosciences
  • ZS Pharma
Market Driver
  • Increase in Associated Disorders with CKD
  • For a full, detailed list, view our report
Market Challenge
  • Genericization of Major Brands
  • For a full, detailed list, view our report
Market Trend
  • Approval of New Pipeline Drugs
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

TechNavio Announces the Publication of its Research Report – Global CKD Drugs Market 2015-2019

TechNavio recognizes the following companies as the key players in the Global CKD Drugs Market: Actavis plc, Amgen Inc., F. Hoffmann-La Roche Ltd., Johnson & Johnson Ltd. and Sanofi SA

Other Prominent Vendors in the market are: Abbott Laboratories, Akebia Therapeutics, AMAG Pharmaceuticals, Cara Therapeutics, FibroGen, Keryx Biopharmaceuticals, OPKO Health, Pharmacosmos, Raptor Pharmaceuticals, Reata Pharmaceuticals, Regulus Therapeutics, Rockwell Medical, Shield Therapeutics, Takeda Pharmaceuticals, Vifor Pharma, Xenetic Biosciences and ZS Pharma.

Commenting on the report, an analyst from TechNavio’s team said: “Approval of new pipelines drugs is one of the key trends being witnessed in this market. The approval of new products gives motivation to the market players and directs their focus toward R&D and innovation. The launch of three new pipeline drugs, ferric citrate, Omontys (peginesatide), and Nulojix (belatacept), is expected to boost the market.”

According to the report, the Global CKD Drugs market is predominantly driven by an increase in associated disorders such as hypertension and diabetes, an increase in the aging population, and unmet needs and side effects. The chance of having CKD increases with age and is most common among those aged over 65 years.

Further, the report states that the major challenge faced by Global CKD Drugs market is the genericization of major brands. This will create space for generic drug manufacturers. Branded CKD drugs are also exempted from Medicare coverage, resulting in patient incompliance.

Companies Mentioned

Actavis, Amgen, F. Hoffmann-La Roche, Johnson & Johnson, Sanofi, Abbott Laboratories, Akebia Therapeutic, AMAG Pharmaceuticals, Cara Therapeutics, FibroGen, KeryxBiopharmaceuticals, OPKO Health, Pharmacosmos, Raptor Pharmaceuticals, Reata Pharmaceuticals, Regulus Therapeutics, Rockwell Medical, Shield Therapeutics,Takeda Pharmaceuticals, Vifor Pharma Ltd, Xenetic Biosciences, ZS Pharma

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
      • Table Segmentation of Global CKD Drugs Market
    • Product Offerings
  • Product Profiles
    • Aranesp
      • Epogen/Procrit
      • Mircera
      • Renvela
      • Avapro
      • Bystolic
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Disease Overview
    • Table Stages of CKD
    • Etiology
      • Table Causes of CKD
    • Epidemiology
      • Mortality
      • Prevalence of CKD
        • Table Prevalence of CKD among NHANES (US) Participants by CKD Stage 1988-2012
  • Pipeline Analysis
    • Emerging Treatment Options
  • Market Landscape
    • Market Overview
    • Market Size and Forecast
      • Table Global CKD Drugs Market 2014-2019 (US$ billion)
      • Table Drivers and Challenges in Global CKD Drugs Market
    • Five Forces Analysis
  • Segmentation of Global CKD Market by Route of Administration
    • Table Segmentation of Global CKD Drugs Market by Route of Administration
    • Oral
    • SC
    • IV
  • Segmentation of Global CKD Market by Mechanism of Action
    • Table Segmentation of Global CKD Drugs Market by Mechanism of Action
    • ARBs
    • ACEIs
    • ESAs
    • PH Binders
    • Vasodilators
  • Geographical Segmentation
    • Table Segmentation of Global CKD Drugs Market by Geography 2014
    • Table Segmentation of Global CKD Drugs Market by Geography 2019
    • Table Segmentation of Global CKD Drugs Market by Geography 2014-2019
    • CKD Drugs Market in Americas
      • Market Size and Forecast
        • Table CKD Drugs Market in Americas 2014-2019 (US$ billion)
    • CKD Drugs Market in EMEA Region
      • Market Size and Forecast
        • Table CKD Drugs Market in EMEA Region 2014-2019 (US$ billion)
    • CKD Drugs Market in APAC Region
      • Market Size and Forecast
        • Table CKD Drugs Market in APAC Region 2014-2019 (US$ billion)
  • Buying Criteria
  • Market Growth Drivers
    • Table Comparison of Percentage of Population Age 65 and Older 2012 and 2050
  • Drivers and their Impact
  • Market Challenges
  • Impact of Drivers and Challenges
  • Market Trends
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
      • Competitive Assessment of Top Drugs Used for CKD Treatment
        • Table Revenue Comparison of Top Drugs Used for Treatment of CKD 2013 (US$ million)
      • Amgen
        • Table Epogen: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
        • Table Aranesp: Revenue Comparison and YoY Growth 2011-2013 (US$ million)
      • Actavis
        • Table Bystolic: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
      • Johnson & Johnson
        • Table Procrit: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
      • F. Hoffmann-La Roche
        • Table Mircera: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
      • Sanofi
        • Table Renvela: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
        • Table Avapro: Revenue Comparison and YoY Growth Rate 2011-2013 (US$ million)
    • Other Prominent Vendors
  • Key Vendor Analysis
    • Amgen
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Amgen: Business Segmentation by Revenue 2013
      • Product Portfolio by Revenue 2013
        • Table Amgen: Product Portfolio by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Amgen: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
      • Geographical Segmentation by Revenue 2013
        • Table Amgen: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Actavis
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Global Chronic Kidney Disease (CKD) Drugs Market Market Business Segmentation 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Global Chronic Kidney Disease (CKD) Drugs Market Business Segmentation by Revenue 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Actavis : Sales by Geography (in US$ million)
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Johnson & Johnson
      • Key Facts
      • Business Overview
      • Business Segmentation by Revenue 2013
        • Table Johnson & Johnson: Business Segmentation by Revenue 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table Johnson & Johnson: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
      • Geographical Segmentation by Revenue 2013
        • Table Johnson & Johnson: Geographical Segmentation by Revenue 2013
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • F. Hoffmann-La Roche Ltd.
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Business Segmentation of F. Hoffmann-La Roche Ltd. 2013
      • Business Segmentation by Revenue 2012 and 2013
        • Table F. Hoffmann-La Roche Ltd.: Business Segmentation by Revenue 2012 and 2013
      • Sales by Geography
        • Table F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Pharmaceuticals Division)
        • Table F. Hoffmann-La Roche Ltd.: Sales by Geography 2013 (Diagnostics Division)
      • Business Strategy
      • Key Information
      • SWOT Analysis
    • Sanofi SA
      • Key Facts
      • Business Description
      • Business Segmentation
        • Table Sanofi SA: Business Segmentation
      • Revenue by Business Segmentation
        • Table Sanofi SA: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
      • Sales by Geography
        • Table Sanofi SA: Sales Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report